A Success Story of EQA Development During the Pandemic

The first requests for EQA for SARS-CoV-2 detection were presented to Aurevia in March 2020. Aurevia was rapidly able to respond to the need for EQA both for SARS-CoV-2 nucleic acid detection and antibody (Ab) detection and the pilot scheme samples were distributed already in May 2020. An EQA scheme for antigen (Ag) detection was conducted in November 2020. The aim of this study is to show how three successful EQA pilots were conducted rapidly during the acute phase of a pandemic.